Jun 10, 2020
MYR Pharmaceuticals has incorporated its first European subsidiary in France
May 29, 2020
MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (bulevirtide), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infections
May 07, 2020
Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 30, 2020
Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda
Apr 01, 2020
Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic
Mar 13, 2020
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Jan 06, 2020
Eiger Updates on 2019 Progress and 2020 Milestones Expected
Nov 12, 2019
Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
Oct 21, 2019
Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019
Aug 20, 2019
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
Aug 08, 2019
Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
Jun 05, 2019
Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development
May 09, 2019
Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
Apr 04, 2019
MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.
Mar 26, 2019
Eiger BioPharmaceuticals to Participate in Conferences in April
Mar 14, 2019
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Mar 05, 2019
MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D Infections
Feb 06, 2019
Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
Dec 18, 2018
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
Dec 17, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection